CP v2

Tag: Depresija

  • Vagus nerve stimulation implant shows lasting gains for treatment-resistant depression, and some patients reach remission

    Vagus nerve stimulation implant shows lasting gains for treatment-resistant depression, and some patients reach remission

    About one in five adults in the United States will experience major depression at some point in their lives. Many people improve after trying a few treatments, but for as many as one-third of patients, standard antidepressants or psychotherapy do not provide enough relief. This condition, known as treatment-resistant depression, can persist for years or even decades. New research now suggests that a small implanted device may offer meaningful and long-lasting improvement for people with the most severe forms of the illness.

    Scientists at Washington University School of Medicine in St. Louis led a large, multicenter clinical trial to evaluate this approach. The researchers found that a device designed to stimulate the vagus nerve was linked to sustained improvements in depressive symptoms, daily functioning, and overall quality of life. For most patients who showed improvement after one year, those gains continued for at least two years.

    The participants in the study had lived with depression for an average of 29 years and had already tried about 13 treatments without success. These included intensive options such as electroconvulsive therapy and transcranial magnetic stimulation, highlighting just how difficult their condition had been to treat.

    The latest results come from the ongoing RECOVER trial and were published Jan. 13 in the International Journal of Neuropsychopharmacology.

    “We believe the sample in this trial represents the sickest treatment-resistant depressed patient sample ever studied in a clinical trial,” said lead author Charles Conway, MD, a professor of psychiatry and director of the WashU Medicine Treatment Resistant Mood Disorders Center. “There is a dire need to find effective treatments for these patients, who often have no other options. With this kind of chronic, disabling illness, even a partial response to treatment is life-altering, and with vagus nerve stimulation we’re seeing that benefit is lasting.”

    How vagus nerve stimulation works

    The RECOVER study was designed to test whether adding vagus nerve stimulation (VNS) to ongoing care could improve outcomes for people with treatment-resistant depression. The therapy involves surgically placing a device under the skin in the chest. The device sends carefully controlled electrical signals to the left vagus nerve — a key communication pathway between the brain and many internal organs.

    The VNS Therapy System is made by LivaNova USA, Inc., which sponsored and funded the RECOVER trial. The study is collecting long-term data on mood, daily function, and quality of life in people with severe treatment-resistant depression. One aim of the research is to help the U.S. Centers for Medicare and Medicaid Services (CMS) decide whether to expand coverage for the therapy. Because many private insurers follow CMS decisions, approval could make the treatment accessible to far more patients, as cost has been a major barrier.

    Inside the RECOVER trial

    Nearly 500 patients were enrolled across 84 locations in the United States. About three-quarters of participants were so severely affected by depression that they were unable to work. All patients received the implanted device, but only half had the device activated during the first year to allow for comparison. Researchers tracked changes in depression severity, quality of life, and everyday functioning.

    A response was considered meaningful if symptoms improved by at least 30% compared with the start of the study. A reduction of 50% or more was classified as a “substantial” response.

    Conway emphasized that even modest improvements can dramatically change a person’s life. Severe depression can leave people feeling “paralyzed by life,” unable to manage basic daily activities and at higher risk of hospitalization or early death.

    Earlier findings from the blinded first year of the trial showed that patients with activated devices spent more time with improved mood, better functioning, and higher quality of life than those whose devices were not active. However, the primary measurement tool (the Montgomery-Åsberg depression scale, which measures the severity of depressive episodes) did not show a statistically significant difference between the two groups.

    Benefits that last over time

    In the newest analysis, the researchers focused on patients whose devices were active from the start of the trial. They wanted to see whether improvements seen at 12 months would continue through 24 months. They also examined whether some patients who did not improve in the first year might respond later with continued treatment.

    Out of 214 patients who received active treatment from the beginning, about 69%, or 147 people, showed a meaningful response at one year in at least one outcome measure. Among those who benefited at 12 months, more than 80% maintained or improved their results by the two-year mark across measures of depression, quality of life, and daily functioning. For patients with a substantial response at one year — defined as at least a 50% reduction in symptoms — 92% were still benefiting at two years.

    Nearly one-third of participants who had not improved after the first year reported benefits by the end of the second year, suggesting that the therapy may take longer to work for some individuals. Relapse rates remained low among those who responded, particularly among the strongest responders.

    The researchers also found that more than 20% of treated patients, or 39 people, were in remission after 24 months. This means their symptoms had eased enough for them to function normally in daily life, a result Conway described as especially notable.

    “We were shocked that one in five patients was effectively without depressive symptoms at the end of two years,” he said. “Seeing results like that for this complicated illness makes me optimistic about the future of this treatment. These results are highly atypical, as most studies of markedly treatment-resistant depression have very poor sustainability of benefit, certainly not at two years. We’re seeing people getting better and staying better.”

    Funding and disclosures

    The study was supported by LivaNova, PLC, the developer and manufacturer of the Vagus Nerve Stimulation therapy system. LivaNova, PLC supported the study design, data analysis, and preparation of the report. The U.S. Centers for Medicare & Medicaid Services approved the study under its NCD VNS for Treatment Resistant Depression. The authors alone made the final decision on the manuscript content and its submission for publication.

    Conway has received research support from the American Foundation for Suicide Prevention, Assurex Health, August Busch IV Foundation, Barnes-Jewish Hospital Foundation, LivaNova, National Institute of Mental Health, and the Taylor Family Institute for Innovative Psychiatric Research. He has also served as a consultant for LivaNova.

  • Why US Midlife Is Getting Harder: Rising Loneliness, Memory Decline, and a Weaker Safety Net

    Why US Midlife Is Getting Harder: Rising Loneliness, Memory Decline, and a Weaker Safety Net

    Middle age is increasingly emerging as a pressure point in the United States, with Americans born in the 1960s and early 1970s reporting more loneliness and depression than earlier generations. Researchers also see declines in episodic memory and physical strength that appear more pronounced than in many other high-income countries.

    The pattern was outlined in cross-national research led by Arizona State University psychologist Frank J. Infurna, which compared survey data across 17 countries. The analysis suggests the US is diverging from peers where midlife health and well-being have generally improved over recent decades.

    Why the US stands out

    A key difference identified by the researchers is the level of public support for families. Many European countries expanded family benefits since the early 2000s, while US spending on comparable supports has been far more limited.

    That gap matters during midlife, when many people are simultaneously managing full-time work, raising children, and helping aging parents. In countries with stronger benefits, midlife loneliness tended to be lower and rose more slowly over time.

    Healthcare costs and financial strain

    Healthcare affordability also appears to play a central role in the US midlife squeeze. Even as the United States spends more per person on healthcare than other wealthy nations, individuals often face higher out-of-pocket costs and more financial exposure.

    The research links these pressures to delayed or skipped care, reduced preventive visits, and higher stress from medical bills and debt. Those dynamics can compound other midlife burdens, including work instability and caregiving responsibilities.

    When education protects less

    Income inequality was another factor associated with worse midlife outcomes, aligning with broader evidence that inequality can weaken health and social ties. The researchers noted that inequality has risen in the United States since the early 2000s, while it has been steadier in much of Europe.

    One of the more striking findings is cognitive: despite higher educational attainment over time, US middle-aged adults showed declines in episodic memory not widely seen in peer countries. The authors suggest chronic stress, financial insecurity, and cardiovascular risk factors may be eroding the protective effect education once provided.

    The study argues these trends are not inevitable, pointing to personal buffers such as stronger social connections and a sense of control over daily life. But it also concludes that policy choices, including paid leave, childcare support and more affordable access to care, are closely tied to how well midlife populations fare.

  • Precision Treatment for Depression: A New Data-Driven Model Aims to Match Patients With the Therapy Most Likely to Work

    Researchers are moving beyond trial-and-error care for depression with a precision approach designed to better match patients to treatments based on individual characteristics. The effort reflects growing evidence that depression symptoms and recovery paths vary widely from person to person.

    The project, led by psychologists at the University of Arizona and Radboud University, draws on patient-level data from randomized clinical trials across the world. Their protocol, published in PLOS One, outlines how they plan to build a clinical decision support tool for adult depression treatment selection.

    Why first-line care often fails

    Standard care frequently begins with a first-line medication or therapy and then shifts if symptoms persist, a process that can take months. The researchers point to prior findings that roughly half of patients do not respond to an initial treatment, highlighting the need for better targeting.

    Instead of offering broad guidelines, the planned tool would generate a single recommendation by weighing multiple factors at once. These include demographic information such as age and gender, along with clinical features like anxiety symptoms or personality-related difficulties.

    What data the model will use

    The team aggregated outcomes from more than 60 clinical trials involving nearly 10 000 patients, covering several widely used interventions. The treatments include antidepressant medications and multiple psychotherapy approaches, such as cognitive therapy, behavioral therapy, interpersonal therapy and short-term psychodynamic therapy.

    By combining many trials, the researchers aim to overcome limits that can affect prediction models built from single studies with smaller samples. They say the work required years of data cleaning and harmonization before analysis could begin.

    When it could reach clinics

    The next step is to develop the algorithm and then test it in a clinical trial to see whether tool-guided care improves outcomes compared with usual practice. If the results hold up, the system could be deployed as a simple software or web-based application used during routine assessments.

    The researchers argue that the inputs are intentionally practical, relying on information that can be collected through standard questionnaires and basic clinical intake. Their longer-term goal is to help clinicians and patients reach effective treatment faster while using existing mental health resources more efficiently.

  • Late-life depression could precede Parkinson’s or Lewy body dementia, Danish study suggests

    Late-life depression could precede Parkinson’s or Lewy body dementia, Danish study suggests

    While there is currently no cure for Parkinson’s disease or Lewy body dementia, addressing depression early could improve quality of life and overall care for patients as these diseases develop.

    study published in General Psychiatry provides the most detailed longitudinal evidence to date, demonstrating that depression frequently precedes the diagnosis of PD and LBD and remains elevated for several years thereafter.

     

    Drawing on comprehensive Danish national health registers, the researchers conducted a retrospective case–control study including 17,711 individuals diagnosed with PD or LBD between 2007 and 2019. Researchers compared these patients with people of similar age and sex who were diagnosed with other long-term conditions, including rheumatoid arthritis, chronic kidney disease, and osteoporosis.

     

    The results showed a clear pattern: depression occurred more often and earlier in people who went on to develop Parkinson’s disease or Lewy body dementia than in those with other chronic illnesses. In the years leading up to diagnosis, the risk of depression rose steadily, peaking in the three years before diagnosis. Even after diagnosis, patients with Parkinson’s disease or Lewy body dementia continued to experience higher rates of depression than the comparison groups.

     

    Importantly, this pattern could not be fully explained by the emotional burden of living with a chronic illness. Other long-term diseases that also involve disability did not show the same strong increase in depression risk. This suggests that depression may be linked to early neurodegenerative changes in the brain, rather than being only a psychological reaction to declining health.

     

    The findings were especially striking for Lewy body dementia, where rates of depression were even higher than in Parkinson’s disease, both before and after diagnosis. Researchers note that differences in disease progression and brain chemistry may help explain this trend.

     

    “Following a diagnosis of PD or LBD, the persistent higher incidence of depression highlights the need for heightened clinical awareness and systematic screening for depressive symptoms in these patients.” first author Christopher Rohde noted “Thus, our main conclusion—that PD/LBD are associated with a marked excess depression risk preceding and following diagnosis when compared with other chronic conditions—remains valid.”

     

    The authors emphasize that this does not mean everyone with depression will develop Parkinson’s disease or dementia. Instead, they recommend greater awareness and closer monitoring when depression appears for the first time in older adults.

     

    While there is currently no cure for Parkinson’s disease or Lewy body dementia, addressing depression early could improve quality of life and overall care for patients as these diseases develop.

  • Teen Diet and Depression Risk: A Major Review Points to Whole Foods Over Supplements

    Teen Diet and Depression Risk: A Major Review Points to Whole Foods Over Supplements

    A major review led by Swansea University researchers suggests teenagers’ overall diet quality may be linked to mental health, with healthier eating patterns more often associated with fewer depressive symptoms. The findings add to growing interest in nutrition as a modifiable factor that could support adolescent wellbeing.

    Published in the journal Nutrients, the paper assessed evidence from 19 earlier studies examining diet and mental health in adolescents. Across the studies, lower-quality diets were more frequently connected with higher psychological distress, though results varied by design and population.

    Whole-diet patterns stand out

    The review included six randomized controlled trials and 13 prospective cohort studies, allowing the authors to compare different types of evidence. While some studies hinted that specific supplements such as vitamin D might reduce depressive symptoms, the overall picture for individual nutrients was inconsistent.

    By contrast, broader dietary patterns showed clearer and more repeatable signals. The authors argue that focusing on overall balance and quality may be more useful than targeting single nutrients, particularly when translating research into school, family, and public health settings.

    Why adolescence is a key window

    Researchers highlighted adolescence as a critical period for brain development and emotional regulation, when depression symptoms can emerge and become entrenched. Because diet is part of daily life and can be shaped at scale, they see it as a practical area for prevention and early support.

    At the same time, the review notes that diet and mental health do not exist in isolation. Socioeconomic factors and sex differences may influence both what teens eat and how mental health outcomes present, complicating cause-and-effect interpretation.

    What the evidence still misses

    The authors flagged major gaps, including a heavy focus on depression compared with other outcomes such as anxiety, stress, self-esteem, externalizing behavior, and aggression. They also emphasized the need for more standardized methods and improved reporting so results can be compared across studies.

    To strengthen future conclusions, the team proposed a research roadmap that includes exposure-based designs, biological markers, and open science practices. In a statement, corresponding author Hayley Young said, “Overall, our findings suggest that public health and clinical strategies should prioritise whole-diet approaches over isolated supplementation when considering adolescent mental health.”

    The researchers cautioned that more high-quality studies are needed to determine which dietary patterns work best, and for whom. Even so, the review suggests that everyday food choices may play a bigger role in teen mental health than many families and clinicians have assumed.

  • Exercise emerges as a leading option for depression and anxiety, with group programs showing the biggest gains

    Exercise emerges as a leading option for depression and anxiety, with group programs showing the biggest gains

    A major evidence review in the British Journal of Sports Medicine reports that structured exercise can meaningfully reduce symptoms of depression and anxiety, often performing as well as established treatments. The authors assessed a large body of randomized trial data to compare different exercise types, intensities and settings.

    The umbrella review combined results from dozens of prior meta-analyses, covering hundreds of individual trials and tens of thousands of participants across a wide age range. Overall, the synthesis found a medium-sized improvement in depression symptoms and a small-to-medium improvement in anxiety.

    Which workouts seemed most effective

    Aerobic exercise such as running, swimming and dance stood out for depression, particularly when sessions were supervised or done in groups. For anxiety, shorter programs lasting up to about 8 weeks and using lower-intensity activity appeared to deliver the most consistent benefits.

    Researchers also found improvements across resistance training and mind-body approaches such as yoga, tai chi and qigong, as well as mixed programs that combine formats. Effects were observed regardless of sex, suggesting exercise can be broadly useful, even if the best “fit” varies by person.

    Who benefited most in the data

    The strongest reductions were reported among young adults ages 18 to 30 and among women after giving birth, groups that also face elevated risks of mood and anxiety symptoms. The authors note that social and practical factors, including support and accountability, may help explain why group formats performed well.

    While the results were generally comparable to medication or talking therapies, the study does not argue that exercise should replace clinical care for everyone. Instead, it points to exercise as a credible first-line or add-on option, especially where access to therapy or medication is limited or where people prefer non-drug approaches.

    Limits and what comes next

    The authors caution that definitions of intensity, frequency and program length differed across studies, making precise prescriptions harder to standardize. Some age groups and exercise formats were also represented by less pooled data than others.

    Even with those caveats, the review strengthens the case for tailoring exercise to individual needs, including supervision, setting and duration. Clinicians increasingly emphasize that the most effective program is one a person can start safely and sustain, while tracking symptoms and overall wellbeing.

  • Major Lancet review questions medicinal cannabis for anxiety and PTSD as trial evidence falls short

    Major Lancet review questions medicinal cannabis for anxiety and PTSD as trial evidence falls short

    A large review in The Lancet concludes there is no convincing evidence that medicinal cannabis improves symptoms of anxiety, depression or post-traumatic stress disorder. Researchers say the balance of data from randomized trials does not support routine prescribing for these mental health conditions.

    The analysis arrives as medical cannabis use has expanded rapidly in North America and elsewhere, including among people seeking relief from mood and trauma-related symptoms. The authors note that patient demand has often moved faster than the clinical evidence base.

    What the review examined

    The study pooled results from 54 randomized controlled trials conducted between 1980 and 2025, making it one of the broadest assessments of cannabinoids across mental health indications to date. It focused on both effectiveness and safety outcomes, comparing cannabis-based medicines with placebo or other controls.

    According to the authors, the evidence did not show meaningful improvements for anxiety, depression or PTSD when results were combined. They also cautioned that frequent use could be associated with harms, including psychotic symptoms and cannabis use disorder, and may delay more effective care.

    Potential benefits, but limited certainty

    The review found tentative signals that some cannabinoid preparations could help in a small number of other conditions, such as insomnia, tics or Tourette’s syndrome, autism-related symptoms, and cannabis use disorder. However, the authors stressed that the overall quality of evidence for these indications was low.

    They also pointed to areas where cannabis-based treatment is supported by stronger evidence, including specific epilepsy syndromes treated with cannabidiol, spasticity in multiple sclerosis, and certain types of pain. Even in these areas, they emphasized the need to match products and dosing to conditions studied in rigorous trials.

    Safety questions and regulation debate

    The authors said the findings should inform clinicians weighing prescriptions for mental health, particularly given varying product potency and formulations across markets. They argued that inconsistent regulation and marketing claims can leave patients with unclear expectations about benefits and risks.

    In substance use disorders, results differed by condition, with some evidence suggesting oral cannabinoid medicines may reduce cannabis smoking when combined with psychological therapy. But for cocaine-use disorder, the review reported increased cravings, indicating cannabis medicines should not be used for that purpose.

    Researchers called for clearer prescribing guidance and more high-quality trials that measure standardized mental health outcomes over longer follow-up periods. Until then, they said established, evidence-based treatments for anxiety, depression and PTSD should remain first-line care.

  • Ozempic and other GLP-1 drugs linked to lower depression and addiction risk in large Swedish study

    Ozempic and other GLP-1 drugs linked to lower depression and addiction risk in large Swedish study

    GLP-1 medications, such as semaglutide (Ozempic, Wegovy, and Rybelsus), commonly prescribed for diabetes and obesity may also be linked to better mental health outcomes, according to new research. The study found that people using these drugs had fewer psychiatric hospital visits and took less time off work due to mental health issues. The large-scale analysis was conducted by researchers from the University of Eastern Finland, Karolinska Institutet in Stockholm, and Griffith University in Australia.

    Obesity and diabetes are both tied to a higher risk of mental health problems. At the same time, people with psychiatric disorders are more likely to develop metabolic conditions such as obesity and diabetes. Scientists have long been exploring how these conditions overlap and whether treatments for physical health might also influence mental well-being.

    To investigate this connection, researchers analyzed data from nearly 100,000 individuals, including more than 20,000 who had used GLP-1 medications. Participants were tracked using Swedish national health registers from 2009 to 2022.

    Reduced Depression Anxiety and Psychiatric Care

    The findings showed that GLP-1 medications, especially semaglutide, were associated with fewer psychiatric-related hospital visits and reduced sickness absence. During periods when people were taking semaglutide, the need for such care dropped by 42% compared to periods without GLP-1 use. The risk of depression was 44% lower, while anxiety disorders were reduced by 38%.

    Lower Risk of Substance Use and Suicidal Behavior

    The study also found a notable decrease in substance use disorders among semaglutide users. Hospital care and time off work related to substance use were 47% lower during treatment periods. In addition, GLP-1 receptor agonists were linked to a reduced risk of suicidal behavior.

    One of the study’s authors, Professor Mark Taylor from Griffith University, said the findings were not entirely unexpected: “An earlier study examining Swedish registers found the use of GLP-1 medications to be associated with a reduced risk of alcohol use disorder. Alcohol-related problems often have downstream effects on mood and anxiety, so we expected the effect to be positive on these as well.”

    Why Might These Drugs Affect the Brain

    Even so, the strength of the associations surprised the research team. “Because this is a registry-based study, we cannot determine exactly why or how these medications affect mood symptoms, but the association was quite strong. It is possible that, in addition to factors such as reduced alcohol consumption, weight loss-related improvements in body image, or relief associated with better glycemic control in diabetes, there may also be direct neurobiological mechanisms involved — for example, through changes in the functioning of the brain’s reward system,” said Research Director, Docent Markku Lähteenvuo from the University of Eastern Finland.

    Strong Evidence but More Research Needed

    The results were published in The Lancet Psychiatry, a leading journal in the field. While earlier studies on GLP-1 medications and mental health have produced mixed findings, many of those studies were smaller. This large registry-based analysis adds stronger evidence, though further research is still needed to fully understand the link.

  • Ozempic and other GLP-1 drugs tied to lower depression and anxiety in large Swedish study, raising new questions about mental health benefits

    Ozempic and other GLP-1 drugs tied to lower depression and anxiety in large Swedish study, raising new questions about mental health benefits

    Popular GLP-1 medicines used for type 2 diabetes and weight loss, including Ozempic and Wegovy, may be linked to improved mental health outcomes, according to a large new analysis of Swedish health data. Researchers tracked changes in psychiatric care and work absence during periods when patients were using these drugs.

    The study, led by scientists from the University of Eastern Finland, Karolinska Institutet and Griffith University, examined national register data spanning 2009 to 2022. Nearly 100 000 people were included, with more than 20 000 having used a GLP-1 receptor agonist at some point during follow-up.

    What the study found

    Across the dataset, GLP-1 use was associated with fewer psychiatric hospital visits and fewer days of sickness absence related to mental health conditions. The strongest associations were reported for semaglutide, the active ingredient in Ozempic and Wegovy.

    During periods of semaglutide use, psychiatric hospital care and sickness absence were reported as 42% lower than during periods off treatment. The analysis also linked semaglutide exposure with a 44% lower risk of depression and a 38% lower risk of anxiety disorders.

    Signals beyond mood and anxiety

    The researchers also reported a lower rate of hospital care and work absence tied to substance use disorders during semaglutide treatment periods, with a reduction of 47%. They additionally found an association between GLP-1 receptor agonist use and reduced suicidal behavior, though the study design cannot determine causality.

    One author, Professor Mark Taylor of Griffith University, said the direction of the results aligned with earlier register-based research suggesting GLP-1 use may be associated with a reduced risk of alcohol use disorder. Because alcohol problems can worsen mood symptoms, the team said this could be one pathway behind the observed patterns.

    Why it may happen, and what it means

    Experts caution that registry studies can show links but cannot prove the drugs directly prevent depression or anxiety, since unmeasured factors could influence who starts or stays on treatment. Researchers said potential explanations range from improved blood sugar control and weight loss to reduced alcohol use and better quality of life.

    They also pointed to possible direct effects on the brain, including changes in reward-related pathways, as a hypothesis that needs targeted clinical research. The findings were published in The Lancet Psychiatry, adding weight to an ongoing debate as regulators and clinicians continue to watch for both potential benefits and risks affecting mental health.

  • A simple blood test could spot depression risk early by tracking immune cell aging

    A simple blood test could spot depression risk early by tracking immune cell aging

    Researchers are testing whether a routine blood sample could help flag depression earlier, using measures of biological aging in specific immune cells. The work adds to a growing push for objective biomarkers that could complement symptom-based mental health screening.

    The study, published in The Journals of Gerontology: Series A, examined epigenetic changes that act like molecular timestamps on DNA. These so-called epigenetic clocks estimate biological age, which can advance faster than chronological age under stress, illness, or other factors.

    Why depression has been hard to test

    Depression is typically diagnosed through clinical interviews and questionnaires, not lab confirmation, partly because the condition can look very different across patients. Some people primarily experience somatic symptoms such as sleep and appetite changes, while others struggle most with mood and cognition, including hopelessness and loss of pleasure.

    That variability can complicate detection, especially when physical symptoms overlap with other chronic conditions. Clinicians may order bloodwork to rule out medical causes, but there is still no widely accepted biological test that can confirm depression on its own.

    Monocytes emerge as a key signal

    The research analyzed data from 440 women, including 261 living with HIV and 179 without HIV, drawing on the long-running Women’s Interagency HIV Study. Depression symptoms were assessed using the Center for Epidemiologic Studies Depression Scale, a 20-item tool that captures both somatic and non-somatic features.

    Blood samples were used to calculate epigenetic aging in two ways: a broad measure across multiple cell types and a monocyte-focused clock. Monocytes are white blood cells involved in immune responses and inflammation, processes increasingly studied for their links to mental health.

    The monocyte-specific aging measure tracked most strongly with non-somatic depression symptoms such as anhedonia, hopelessness, and a sense of failure, in women with and without HIV. By contrast, the broader multi-tissue aging measure did not show the same relationship, suggesting the signal may be cell-type specific.

    What this could change in care

    The authors caution that the findings are not yet ready for clinical use and do not mean a single blood draw can diagnose depression today. Larger studies, replication in different populations, and clearer thresholds would be needed before a test could be validated for real-world screening.

    Still, the results point to a possible path toward earlier, more precise detection, particularly for people whose physical symptoms might be attributed to other illnesses. If confirmed, immune-cell epigenetic measures could also support more personalized care by helping researchers distinguish depression subtypes and refine treatment matching.